Synagis is a drug used to lessen the severity of a Respiratory Syncytial Virus infection. It is not a vaccine to prevent Respiratory Syncytial Virus; its main purpose is to decrease the likelihood of a lower respiratory infection due to a Respiratory Syncytial Virus infection.

Synagis is given to infants through intramuscular injections. Injections are given monthly for six months, usually beginning in September or October, the beginning of Respiratory Syncytial Virus season.

The Food & Drug Administration approved Synagis in June of 1998. MedImmune, Inc., a Maryland corporation, manufactures Synagis.

Side effects associated with Synagis injections include, but may not be limited to, fever, nervousness and skin reaction at the injection site.

In November 2002, FDA and MedImmune revised the WARNINGS, OVERDOSAGE, and POST MARKETING EXPERIENCE sections of the Synagis label to provide clarification on the risk of anaphylaxis (hypersensitivity) based on worldwide post-marketing experience. Very rare cases of anaphylaxis have been reported following re-exposure to Synagis. Rare severe acute hypersensitivity reactions have also been reported on initial exposure or re-exposure to Synagis. The labeling was also revised to reflect that adverse events after a sixth or greater dose of Synagis are similar in character and frequency to those after the initial five doses.

See your doctor if you have experienced serious side effects associated with Synagis. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.



See Also

  1. Respiratory Syncytial Virus or RSV Drugs: Overview
  Name Size